

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following drug types best describes the mechanism of action of torvutatug samrotecán (AZD5335)?**
  - CLDN6-targeting antibody-drug conjugate (ADC)
  - FR $\alpha$ -targeting ADC**
  - HER2-targeting ADC
- 2. In the Phase III ENGOT-OV65/KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab for patients with platinum-ineligible ovarian cancer, which of the following efficacy outcomes was reported across all patient groups?**
  - Inferior overall survival (OS)
  - A numerical but nonsignificant improvement in OS
  - A statistically significant improvement in OS**
  - No change in OS
- 3. In the Phase III trial evaluating relacorilant and *nab* paclitaxel versus *nab* paclitaxel alone for platinum-resistant ovarian cancer, which of the following efficacy outcomes was reported among patients who had experienced disease progression on a PARP inhibitor?**
  - Inferior progression-free survival (PFS)
  - A numerical but nonsignificant improvement in PFS
  - A statistically significant improvement in PFS**
  - No change in PFS
- 4. The Phase III DESTINY-Ovarian01 study is evaluating trastuzumab deruxtecan with bevacizumab versus bevacizumab alone for patients with Stage III or IV ovarian cancer in which of the following settings?**
  - First-line maintenance treatment for all patients
  - First-line maintenance treatment for patients with HER2 expression**
  - Second-line treatment for all patients
  - Second-line treatment for patients with HER2 expression
- 5. The Phase III MIRASOL trial evaluating mirvetuximab soravtansine versus investigator's choice of chemotherapy for patients with FR $\alpha$ -positive, platinum-resistant ovarian cancer reported which of the following efficacy outcomes?**
  - Inferior OS
  - A numerical but nonsignificant improvement in OS
  - A statistically significant improvement in OS**
  - No change in OS